Complement activation by Proteus mirabilis negatively charged lipopolysaccharides.
Proteus mirabilis strains are human pathogens responsible for urinary tract infections and bacteremias and may be involved in rheumatoid arthritis. Lipopolysaccharide (LPS, bacterial endotoxin), the major component of the cell wall, is one of the virulence factors of Proteus. In the presented studies, we have investigated complement activation by LPSs isolated from P. mirabilis O10, O23, O30, and O43 strains, which differ in the number of negative COO- groups on their polysaccharide components. Four P. mirabilis strains studied were sensitive to complement-mediated killing, despite complement binding by their LPSs. The optimal complement binding by LPSs was detected in serum with functional assays for both the classical and alternative pathways. Complement activation in 80% serum by the smooth, uronic acid, and hexosamine containing P. mirabilis LPSs was not critically determined by the structure of their O-chain polysaccharides. One of four LPSs used as a model, P. mirabilis O10 LPS, fragmented C3 in an LPS dose- and time-dependent manner. It was detected by crossed-immunoelectrophoresis and capture ELISA with anti-C3c antibodies. The lower complement activation by 023 LPS correlates with its reduced C3 fragmentation, compared with three other Proteus LPSs studied. Rabbit anti-O antibodies enhanced the complement binding and factor C3 fragmentation by O10, O23, O30, and O43 P. mirabilis LPSs.
Kaca
W
W
Karolinska Institutet, Division of Clinical Bacteriology, Huddinge University Hospital, Sweden. wkaca@wirus.cmiwpan.lodz.pl
Literacka
E
E
Sjöholm
A G
AG
Weintraub
A
A
D000818:Animals; D000907:Antibodies, Bacterial / Q000276:immunology / Q000494:pharmacology; D001769:Blood; D002240:Carbohydrate Sequence; D003167:Complement Activation; D003176:Complement C3 / Q000737:chemistry / Q000276:immunology; D015941:Complement Hemolytic Activity Assay; D004591:Electrophoresis, Polyacrylamide Gel; D004797:Enzyme-Linked Immunosorbent Assay; D006801:Humans; D015151:Immunoblotting; D008070:Lipopolysaccharides / Q000737:chemistry / Q000276:immunology* / Q000494:pharmacology; D008969:Molecular Sequence Data; D019081:O Antigens / Q000276:immunology; D011513:Proteus mirabilis / Q000235:genetics / Q000276:immunology / Q000472:pathogenicity*; D013997:Time Factors
D000907:Antibodies, Bacterial; D003176:Complement C3; D008070:Lipopolysaccharides; D019081:O Antigens